Literature DB >> 24560788

Differential ability to resist to complement lysis and invade host cells mediated by MBL in R4 and 860 strains of Trypanosoma cruzi.

Ingrid Evans-Osses1, Andres Mojoli1, Marcia Holsbach Beltrame2, Denise Endo da Costa2, Wanderson Duarte DaRocha3, Thirumalaisamy P Velavan4, Iara de Messias-Reason2, Marcel Ivan Ramirez5.   

Abstract

To produce an infection Trypanosoma cruzi must evade lysis by the complement system. During early stages of infection, the lectin pathway plays an important role in host defense and can be activated by binding of mannan-binding lectin (MBL) to carbohydrates on the surface of pathogens. We hypothesized that MBL has a dual role during parasite-host cell interaction as lectin complement pathway activator and as binding molecule to invade the host cell. We used two polarized strains of T. cruzi, R4 (susceptible) and 860 (resistant) strains, to investigate the role of MBL in complement-mediated lysis. Interestingly R4, but not 860 metacyclic strain, markedly increases the invasion of host cells, suggesting that MBL drives the invasion process while the parasite deactivates the Lectin complement pathway.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chagas disease; Complement system; Inate immunity; Mannan binding lectin; Parasite–host cell interaction

Mesh:

Substances:

Year:  2014        PMID: 24560788     DOI: 10.1016/j.febslet.2014.01.054

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

Review 1.  Escaping Deleterious Immune Response in Their Hosts: Lessons from Trypanosomatids.

Authors:  Anne Geiger; Géraldine Bossard; Denis Sereno; Joana Pissarra; Jean-Loup Lemesre; Philippe Vincendeau; Philippe Holzmuller
Journal:  Front Immunol       Date:  2016-05-31       Impact factor: 7.561

2.  Human complement receptor type 1 (CR1) protein levels and genetic variants in chronic Chagas Disease.

Authors:  Thaisa Lucas Sandri; Kárita Cláudia Freitas Lidani; Fabiana Antunes Andrade; Christian G Meyer; Peter G Kremsner; Iara J de Messias-Reason; Thirumalaisamy P Velavan
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

Review 3.  Trypanosoma cruzi Evades the Complement System as an Efficient Strategy to Survive in the Mammalian Host: The Specific Roles of Host/Parasite Molecules and Trypanosoma cruzi Calreticulin.

Authors:  Galia Ramírez-Toloza; Arturo Ferreira
Journal:  Front Microbiol       Date:  2017-09-01       Impact factor: 5.640

4.  Complement system contributes to modulate the infectivity of susceptible TcI strains of Trypanosoma cruzi.

Authors:  Ruben D Arroyo-Olarte; Ignacio Martínez; Mayra Cruz-Rivera; Fela Mendlovic; Bertha Espinoza
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-02-19       Impact factor: 2.743

Review 5.  Autoimmunity in Chronic Chagas Disease: A Road of Multiple Pathways to Cardiomyopathy?

Authors:  Elidiana De Bona; Kárita Cláudia Freitas Lidani; Lorena Bavia; Zahra Omidian; Luiza Helena Gremski; Thaisa Lucas Sandri; Iara J de Messias Reason
Journal:  Front Immunol       Date:  2018-08-06       Impact factor: 7.561

6.  Human collectin-11 (COLEC11) and its synergic genetic interaction with MASP2 are associated with the pathophysiology of Chagas Disease.

Authors:  Thaisa Lucas Sandri; Fabiana Antunes Andrade; Kárita Cláudia Freitas Lidani; Elias Einig; Angelica Beate Winter Boldt; Benjamin Mordmüller; Meral Esen; Iara J Messias-Reason
Journal:  PLoS Negl Trop Dis       Date:  2019-04-17

Review 7.  Is It Possible to Intervene in the Capacity of Trypanosoma cruzi to Elicit and Evade the Complement System?

Authors:  Galia Ramírez-Toloza; Lorena Aguilar-Guzmán; Carolina Valck; Smrithi S Menon; Viviana P Ferreira; Arturo Ferreira
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 8.  The Interactions of Parasite Calreticulin With Initial Complement Components: Consequences in Immunity and Virulence.

Authors:  Galia Ramírez-Toloza; Lorena Aguilar-Guzmán; Carolina Valck; Viviana P Ferreira; Arturo Ferreira
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.